Tesla MedBed Center at Butler-PA
Welcome,         Profile    Billing    Logout  
 7 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liu, James
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT04588545: Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Recruiting
1/2
39
US
Radiation Therapy, Pertuzumab, Trastuzumab
H. Lee Moffitt Cancer Center and Research Institute, Genentech, Inc.
HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
07/25
07/25
MCC-20899, NCT04923542: Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

Recruiting
1/2
31
US
Stereotactic Radiosurgery (SRS), Abemaciclib, Verzenio, Ramiven, Endocrine therapy, hormone therapy
H. Lee Moffitt Cancer Center and Research Institute, Eli Lilly and Company
Brain Metastases, HR+ Metastatic Breast Cancer
03/25
03/26
NCT05664243: A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
4
US
Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells
In8bio Inc.
Glioblastoma
12/25
12/25
NCT06463184: Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)

Withdrawn
1
12
NA
Xevinapant, Debio 1143
H. Lee Moffitt Cancer Center and Research Institute, EMD Serono Research & Development Institute, Inc.
Recurrent High-grade Glioma
06/27
06/27
CA209-6D9, NCT05704933: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Active, not recruiting
1
16
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab + Relatlimab, Opdualag, Standard of Care Craniotomy
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Metastatic Melanoma, Metastasis to Brain
06/24
06/25
Jackson, Jessica
No trials found
Smotrys, Mariola
No trials found

Download Options